Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7104)
All Articles published online
|
Publishing Process of This Article
|
Apr 15, 2013 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes 2013; 4(2): 19-26 [PMID: 23593532 DOI: 10.4239/wjd.v4.i2.19] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v4/i2/19.htm |
| Number | Citing Articles |
| 1 |
Mehdi Mazloumi, Morteza Entezari, Sanam Samadikhadem, Alireza Ramezani, Homayoun Nikkhah, J. Fernando Arevalo. SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS OF RETINAL HYPERPERMEABILITY AND CHOROIDAL INFLAMMATION AS PREDICTORS OF SHORT-TERM FUNCTIONAL AND ANATOMICAL OUTCOMES IN EYES WITH DIABETIC MACULAR EDEMA TREATED WITH INTRAVITREAL BEVACIZUMAB. Retina 2022; 42(4): 760 doi: 10.1097/IAE.0000000000003361
|
| 2 |
Nurgül Örnek, Mikail Inal, Inci Elif Erbahceci, Tevfik Oğurel, Kemal Örnek. Effect of Intravitreal Bevacizumab on Retrobulbar Blood Flow of Patients with Diabetic Macular Edema. European Journal of Ophthalmology 2015; 25(6): 539 doi: 10.5301/ejo.5000617
|
| 3 |
J Fernando Arevalo, Andres F Lasave, Lihteh Wu, Dhariana Acon, Michel E Farah, Roberto Gallego-Pinazo, Arturo A Alezzandrini, Veronica Fortuna, Hugo Quiroz-Mercado, Guillermo Salcedo-Villanueva, Mauricio Maia, Martin Serrano, Sergio Rojas. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group. British Journal of Ophthalmology 2016; 100(12): 1605 doi: 10.1136/bjophthalmol-2015-307950
|
| 4 |
Julio A. Urrets-Zavalía, Evangelina Espósito, Iliana Garay, Rodolfo Monti, Alejandro Ruiz-Lascano, Leandro Correa, Horacio M. Serra, Andrzej Grzybowski. The eye and the skin in endocrine metabolic diseases. Clinics in Dermatology 2016; 34(2): 151 doi: 10.1016/j.clindermatol.2015.12.001
|
| 5 |
Rehan M Hussain, Thomas A. Ciulla. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opinion on Emerging Drugs 2017; 22(3): 235 doi: 10.1080/14728214.2017.1362390
|
| 6 |
Kuan Hao Yee, Srinivasan Sanjay. Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?. EMJ Diabetes 2017; : 118 doi: 10.33590/emjdiabet/10313316
|
| 7 |
Alessandro ARRIGO, Emanuela ARAGONA, Francesco BANDELLO. Intravitreal treatments for exudative maculopathies: the efficacy/durability dilemma. Minerva Ophthalmology 2024; 66(1) doi: 10.23736/S2785-1265.23.01881-5
|
| 8 |
Maria Assunta Potenza, Carmela Nacci, Maria Antonietta De Salvia, Luca Sgarra, Massimo Collino, Monica Montagnani. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options. Pharmacological Research 2017; 120: 226 doi: 10.1016/j.phrs.2017.04.009
|
| 9 |
Alessandro Arrigo, Emanuela Aragona, Francesco Bandello. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Annals of Medicine 2022; 54(1): 1089 doi: 10.1080/07853890.2022.2064541
|
| 10 |
Lauren M. Ciulla, Nimesh A. Patel, Nicolas A. Yannuzzi, Rehan M. Hussain. Diabetic Eye Disease - From Therapeutic Pipeline to the Real World. 2022; doi: 10.5772/intechopen.99749
|
| 11 |
Rehan M. Hussain, Thomas A. Ciulla. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opinion on Biological Therapy 2016; 16(3): 365 doi: 10.1517/14712598.2016.1131265
|
| 12 |
Joel Hanhart, Itay Chowers. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Reports in Ophthalmology 2015; 6(1): 44 doi: 10.1159/000375230
|
| 13 |
Jiasheng Yang, Guanfang Wang, Xu Xiao, Meihua Bao, Geng Tian, Ali Mohammad Alqudah. Explainable ensemble learning method for OCT detection with transfer learning. PLOS ONE 2024; 19(3): e0296175 doi: 10.1371/journal.pone.0296175
|
| 14 |
Bogumiła Sędziak-Marcinek, Sławomir Teper, Elżbieta Chełmecka, Adam Wylęgała, Mateusz Marcinek, Mateusz Bas, Edward Wylęgała, Irini Chatziralli. Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence. Journal of Diabetes Research 2021; 2021: 1 doi: 10.1155/2021/6620122
|
| 15 |
Alessandro Arrigo, Francesco Bandello. Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. Pharmaceutics 2021; 13(7): 1102 doi: 10.3390/pharmaceutics13071102
|
| 16 |
Murat Okutucu, Hüseyin Fındık, Mehmet Gökhan Aslan, Medeni Arpa. Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects?. BMC Ophthalmology 2021; 21(1) doi: 10.1186/s12886-021-01989-1
|
| 17 |
Francisco Rosa Stefanini, Emmerson Badaró, Paulo Falabella, Michael Koss, Michel Eid Farah, Maurício Maia. Anti-VEGF for the Management of Diabetic Macular Edema. Journal of Immunology Research 2014; 2014: 1 doi: 10.1155/2014/632307
|
| 18 |
Bogumiła Sędziak-Marcinek, Adam Wylęgała, Elżbieta Chełmecka, Edward Wylęgała, Sławomir Teper. How to Achieve Near-Normal Visual Acuity with Bevacizumab in Diabetic Macular Edema Patients. Journal of Clinical Medicine 2021; 10(16): 3572 doi: 10.3390/jcm10163572
|
| 19 |
Yi Liu, Qiuyan Zhu, Pengfei Jiang, Yang Yang, Mingyun Wang, Hao Liang, Qinghua Peng, Qiuyan Zhang. Bibliometric and visualized analysis of DME from 2012 to 2022. Medicine 2024; 103(13): e37347 doi: 10.1097/MD.0000000000037347
|
| 20 |
Oluwaranti Akiyode, Christine Tran. Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications. Diabetes Spectrum 2016; 29(1): 44 doi: 10.2337/diaspect.29.1.44
|
| 21 |
Emre Güler, Ramazan Yağcı. Diabetic macular edema: Efficacy and safety of anti-vascular endothelial growth factor therapy. World Journal of Ophthalmology 2015; 5(3): 133-141 doi: 10.5318/wjo.v5.i3.133
Abstract(904) |
Core Tip(838) |
Full Article(HTML)(2367)
|
Full Article (PDF)-990K(405)
|
Full Article (Word)-210K(273)
|
Peer-Review Report-115K(220)
|
Answering Reviewers-224K(178)
|
Times Cited (0)
|
Total Visits (7691)
|
Open
|
| 22 |
Kuan Hao Yee, Srinivasan Sanjay. Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?. EMJ Diabetes 2017; : 126 doi: 10.33590/emjdiabet/10314891
|
| 23 |
Zhu-Hong Zhang, Qing-Zhong Chen, Feng Jiang, Todd A. Townsend, Chun-Jie Mao, Cai-Yun You, Wen-Hui Yang, Zhi-Yong Sun, Jin-Guo Yu, Hua Yan. Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy. Molecular Medicine Reports 2017; 15(2): 573 doi: 10.3892/mmr.2016.6048
|
| 24 |
Magdalena Hunt, Sławomir Teper, Adam Wylęgała, Edward Wylęgała, Nikolaos Papanas. Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography. Journal of Diabetes Research 2022; 2022: 1 doi: 10.1155/2022/3547461
|
| 25 |
Huseyin Guzel, Berker Bakbak, Mehmet Talay Koylu, Saban Gonul, Banu Ozturk, Sansal Gedik. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema. Cutaneous and Ocular Toxicology 2017; 36(1): 5 doi: 10.3109/15569527.2016.1140177
|